(HealthDay)—Women undergoing screening breast magnetic resonance imaging (MRI) have larger biopsy rates and considerably decrease most cancers yield findings in contrast with screening mammography alone, no matter private historical past of breast most cancers (PHBC), in line with a research revealed on-line Feb. 12 in JAMA Internal Medicine.
Diana S.M. Buist, Ph.D., M.P.H., from the Kaiser Permanente Washington Health Research Institute in Seattle, and colleagues carried out an observational cohort research of six Breast Cancer Surveillance Consortium registries. Data have been included for a pattern of 812,164 women undergoing a complete of two,048,994 digital mammography and/or breast MRI screening episodes from 2003 by way of 2013. Outcomes have been stratified by PHBC.
The researchers discovered that for women with PHBC, age-adjusted core and surgical biopsy rates have been doubled after MRI versus mammography (57.1 versus 23.6 per 1,000 episodes). The variations have been even bigger for women with out PHBC (84.7 and 14.9 per 1,000 episodes, respectively). In women with PHBC, the ductal carcinoma in situ and invasive biopsy yield was considerably larger after mammography versus MRI episodes (404.6 versus 267.6 per 1,000 episodes); for women with out PHBC, the yield was nonsignificantly greater (279.three versus 214.6 per 1,000 episodes). Regardless of PHBC, high-risk benign lesions have been extra generally recognized after MRI.
“Further work is required to determine women who will profit from screening MRI to make sure a suitable benefit-to-harm ratio,” the authors write.